System, Test, Blood Glucose, Over The Counter(NBW)
一般用血糖値測定システム この日本語名は AI が生成した参考訳です。正式名称は英語の原名です。
137 件
直近 2026.03.18
509 件
0 件
431,342 件
分類情報
| Product Code | NBW |
|---|---|
| デバイス名 | System, Test, Blood Glucose, Over The Counter 一般用血糖値測定システム この日本語名は AI が生成した参考訳です。正式名称は英語の原名です。 |
| デバイスクラス | クラス II |
| 21 CFR 規制番号 | 862.1345 |
| 審査区分 | 510(k)(市販前届出) |
| 医療専門分野 | 臨床化学 |
| 定義 | - |
| フラグ | 該当なし |
| AI分析 | この機器は米国においてクラスIIに分類されており、市販前届出(510(k))の対象となっています。クラスIIは中程度のリスクを有する医療機器区分であり、既存の同等品(プレディケイトデバイス)との実質的同等性を示すことで、市販前承認(PMA)よりも簡略化された手続きで市販が可能となります。 米国市場での動向 510(k)は累計で約510件が届出されており、直近5年間でも約30件、参入企業数は約130社となっています。不具合報告(MDR)は累計約431,000件と多く、その大半は不具合(Malfunction)に関するもので、傷害は約37,900件、死亡は114件、その他は約3,400件です。主な問題としてはFailure to Power Up、Incorrect, Inadequate or Imprecise Result or Readings、High Test Resultsが挙げられています。回収は累計約140件で、クラスIが20件、クラスIIが約40件、クラスIIIは確認されていません。直近5年では約9件の回収があり、最新の回収は2026年2月に開始されています。 この分析は公開データ(openFDA・JMDN 対応情報)をもとに AI が生成した参考情報です。市場データは2026年8月時点の集計に基づきます。 |
関連 product code
同じ 21 CFR 862.1345 に分類される product code(9 件)
| No. | product code | 機器名 | クラス | 専門分野 | 510(k) | PMA | 不具合 | 回収 |
|---|---|---|---|---|---|---|---|---|
| 1 | CGA | Glucose Oxidase, Glucose グルコースオキシダーゼ測定用グルコース分析装置 | II | 臨床化学 | 401 | 16 | 7,604 | 89 件 |
| 2 | CFR | Hexokinase, Glucose ヘキソキナーゼ法グルコース測定用試薬 | II | 臨床化学 | 145 | — | 37,530 | 22 件 |
| 3 | LFR | Glucose Dehydrogenase, Glucose グルコースデヒドロゲナーゼ(グルコース測定用) | II | 臨床化学 | 73 | — | 74,195 | 51 件 |
| 4 | PZI | Prescription Use Blood Glucose Meter For Near-Patient Testing 医療従事者用血糖測定装置(患者近接検査用) | II | 臨床化学 | 14 | — | 139 | 1 件 |
| 5 | CGE | Orthotoluidine, Glucose オルトトルイジン法グルコース測定用試薬 | II | 臨床化学 | 12 | — | — | — |
| 6 | MRV | Drink, Glucose Tolerance ブドウ糖負荷試験用飲料 | II | 臨床化学 | 3 | — | 9 | 3 件 |
| 7 | CFW | Copper Reduction, Glucose | II | 臨床化学 | — | — | — | — |
| 8 | CGD | Ferricyanide, Glucose フェリシアン化物法グルコース分析用試薬(測定装置) | II | 臨床化学 | — | — | 1 | — |
| 9 | PYV | Hospital Continuous Glucose Monitoring System 病院用持続血糖測定システム | II | 臨床化学 | — | — | 1 | — |
機器名の日本語訳は AI により自動生成したものです。正確には英語原文をご確認ください。
類似の国内医療機器(自動推定)
FDA デバイス分類と JMDN 英語名の名称・定義文の類似度から機械的に推定した候補です。日米の当局が定めた公的な対応関係ではなく、参考情報としてご覧ください。
| No. | 類別 | 一般的名称 | 品目数 | 企業数 | 年間総出荷額 | 成長率 | 平均価格 | 国産比率 |
|---|---|---|---|---|---|---|---|---|
| 1 | 体液検査用器具 | グルコースモニタシステムクラスⅢ | 12 | 7 | 422.2 億円/年 | +14.0% | 5,846 円/個 | 0.0% |
| 2 | 血液検査用器具 | 自己検査用グルコース測定器クラスⅢ | 44 | 13 | 15.67 億円/年 | -20.4% | 2,274 円/個 | 82.2% |
| 3 | 血液検査用器具 | グルコース分析装置クラスⅠ | 45 | 13 | 6.27 億円/年 | -57.5% | 7.01 万円/個 | 89.1% |
| 4 | 尿検査又は糞便検査用器具 | 自己検査用尿糖計クラスⅡ | 1 | 1 | — | — | — | — |
FDA のデバイスクラスは 3 段階(クラス I〜III)、日本の医療機器は 4 段階(クラス I〜IV)で分類されており、 1 対 1 では対応しません。 リスク区分の考え方が異なるため、参考情報としてご利用ください。
米国での回収・承認・不具合報告
米国回収
全 137 件| 回収番号 | クラス | 回収開始日 | 企業 | 理由 | ステータス |
|---|---|---|---|---|---|
| Z-1548-2026 NBW | クラス I(最重篤) | 2026.02.06 | Trividia Health, Inc. | The system labeling (user manual and online labeling) did not provide adequate directions for lay users to act on the E-5 error code. The error code description and recommended actions for the E-5 error code in the labeling do not: (a) clearly emphasize that an E-5 error code could represent a very high blood glucose level, and (b) prominently convey the appropriate immediate actions, such as contacting a healthcare professional. This could lead to a delay in treatment if the user does not seek medical attention immediately when receiving an E-5 error code and experiencing symptoms of high glucose. | 対応中 |
| Z-1547-2026 NBW | クラス I(最重篤) | 2026.02.06 | Trividia Health, Inc. | The system labeling (user manual and online labeling) did not provide adequate directions for lay users to act on the E-5 error code. The error code description and recommended actions for the E-5 error code in the labeling do not: (a) clearly emphasize that an E-5 error code could represent a very high blood glucose level, and (b) prominently convey the appropriate immediate actions, such as contacting a healthcare professional. This could lead to a delay in treatment if the user does not seek medical attention immediately when receiving an E-5 error code and experiencing symptoms of high glucose. | 対応中 |
| Z-1546-2026 NBW | クラス I(最重篤) | 2026.02.06 | Trividia Health, Inc. | The system labeling (user manual and online labeling) did not provide adequate directions for lay users to act on the E-5 error code. The error code description and recommended actions for the E-5 error code in the labeling do not: (a) clearly emphasize that an E-5 error code could represent a very high blood glucose level, and (b) prominently convey the appropriate immediate actions, such as contacting a healthcare professional. This could lead to a delay in treatment if the user does not seek medical attention immediately when receiving an E-5 error code and experiencing symptoms of high glucose. | 対応中 |
| Z-1545-2026 NBW | クラス I(最重篤) | 2026.02.06 | Trividia Health, Inc. | The system labeling (user manual and online labeling) did not provide adequate directions for lay users to act on the E-5 error code. The error code description and recommended actions for the E-5 error code in the labeling do not: (a) clearly emphasize that an E-5 error code could represent a very high blood glucose level, and (b) prominently convey the appropriate immediate actions, such as contacting a healthcare professional. This could lead to a delay in treatment if the user does not seek medical attention immediately when receiving an E-5 error code and experiencing symptoms of high glucose. | 対応中 |
| Z-0413-2026 NBW | クラス II | 2025.10.07 | Trividia Health, Inc. | Manufacturing defect causing LCD display issues with missing or partial segments (ghosting) that can result in misreading glucose values, potentially leading to inappropriate treatment decisions for diabetes management. | 対応中 |
| Z-1270-2025 NBW | クラス II | 2025.01.30 | Telcare, LLC | Telcare, LLC has received customer complaints related to battery expansion/swelling for its Philips Connected Blood Glucose Meter (i.e., BGM 4 brand name) Monitoring System.. The issue was identified by post market surveillance data (customer complaints) - events of battery expansion/swelling and associated symptoms, e.g., leading to the device's removable back cover (battery port) to separate. If there is a loss of primary function of the device due to the described device defect, an immediate health consequence that may result is prolonged hypoglycemia or hyperglycemia due to delay in treatment, as the blood glucose measurement is not available to guide treatment. In a worst-case situation, there is potential for battery swelling to result in explosion of the battery and/ or device. Exposure to explosion, and subsequently projectiles from the explosion, may result in several immediate health consequences, including concussion, headache, dizziness, eye irritation, blurred vision, eye injury, and vision impairment. | 対応中 |
| Z-2174-2024 NBW | クラス II | 2024.05.13 | Roche Diabetes Care, Inc. | The reason for recall is the meters may show an incorrect measurement unit (mmol/L rather than mg/dL) and may result in the wrong unit of measure. Which may subsequently cause an error in interpreting a result as approximately 18 times lower that the actual blood glucose. Potential immediate health consequences of the glucose meter providing a reading in the wrong units of measurement (UOM) may result in inappropriate rescue therapy for presumed hypoglycemia including urgent and repeat administration of carbohydrates. This in turn could lead to frequent episodes of hyperglycemia which is unrecognized and undertreated.Long range consequences of continued use of the affected meters could include mismanagement of the patient s diabetes for longer periods of time potentially resulting in a major health event (in general persistent and/or severe hyperglycemia) that may lead them to seek medical attention, and depending on the duration of hyperglycemia, could contribute to the development of microvascular (i.e., retinopathy, neuropathy, nephropathy) and/or macrovascular (i.e., myocardial infarction, ischemic stroke) complications of diabetes and could lead to fetal damage (abnormal fetal growth and altered organ development and maturation, fetal hypoxemia, spontaneous abortion, and congenital anomalies) in pregnant women. This issue was identified by three initial consumer complaints, with reports that the meters were presenting the incorrect unit of measure. | 対応中 |
| Z-2211-2023 NBW | クラス II | 2023.05.19 | Ascensia Diabetes Care US, Inc. | Ascensia Diabetes Care has determined through customer complaints that 580 of 2900 meters from lot number DM01T033P are reconfigured from mg/dL to mmol/L. Among them, 579 meters distributed in the United States were packaged into the meter kit and had incorrect factory-set unit of measure where the meters display glucose results in mmol/L rather than mg/dL. The standard unit of measurement for the United States is mg/dL. If a consumer does not notice the incorrect unit of measurement, it is possible that the meters glucose measurement will be read as a lower blood glucose measurement than expected, and this may result in the patients glucose level remaining high, which can potentially lead to an injury requiring immediate medical intervention. | 対応中 |
| Z-1461-2022 NBW | クラス II | 2022.06.21 | Touch US Llc | Device was marketed without FDA 510(k) clearance or a PMA. | 対応中 |
| Z-2354-2021 NBW | クラス II | 2021.07.28 | Roche Diabetes Care, Inc. | Test strip vials may open while inside sealed cartons during shipment. An open vial might expose the test strips to humidity, which might damage the strips and result in inaccurate results, potentially leading to inappropriate therapy decisions and adverse health consequences. | 対応中 |
| Z-1942-2021 NBW | クラス II | 2021.03.16 | Cardinal Health Inc. | Due to shipping delays the devices were exposed to temperature excursions of 31.9¿F, intermittently over a 2 hour and 15 minute period of time which may cause inaccurate results. | 対応中 |
| Z-1938-2021 NBW | クラス II | 2021.03.16 | Cardinal Health Inc. | Due to shipping delays the devices were exposed to temperature excursions of 31.9¿F, intermittently over a 2 hour and 15 minute period of time which may cause inaccurate results. | 対応中 |
| Z-1936-2021 NBW | クラス II | 2021.03.16 | Cardinal Health Inc. | Due to shipping delays the devices were exposed to temperature excursions of 31.9¿F, intermittently over a 2 hour and 15 minute period of time which may cause inaccurate results. | 対応中 |
| Z-2201-2020 NBW | クラス II | 2020.04.20 | Trividia Health, Inc. | One (1) TRUE METRIX AIR blood glucose meter distributed in the United States was packaged into a TRUE METRIX blood glucose meter kit and has an incorrect factory-set unit of measure; the meter displays glucose results in mmol/L rather than mg/dL. | 終了 |
| Z-0999-2020 NBW | クラス II | 2019.12.11 | Roche Diabetes Care, Inc. | Inability to dose the test strips, may result in a temporary inability to get a result that could lead to a delay in treatment and/or therapy decisions | 終了 |
| Z-0998-2020 NBW | クラス II | 2019.12.11 | Roche Diabetes Care, Inc. | Inability to dose the test strips, may result in a temporary inability to get a result that could lead to a delay in treatment and/or therapy decisions | 終了 |
| Z-0997-2020 NBW | クラス II | 2019.12.11 | Roche Diabetes Care, Inc. | Inability to dose the test strips, may result in a temporary inability to get a result that could lead to a delay in treatment and/or therapy decisions | 終了 |
| Z-0835-2020 NBW | クラス II | 2019.12.02 | Polymer Technology Systems, Inc. | One brand of batteries have a small dimensional difference in the negative button terminal, which, when the batteries are inserted incorrectly, can create the possibility for the battery terminals to make reverse contact. This reverse contact can cause a potential for overheating. | 終了 |
| Z-0834-2020 NBW | クラス II | 2019.12.02 | Polymer Technology Systems, Inc. | One brand of batteries have a small dimensional difference in the negative button terminal, which, when the batteries are inserted incorrectly, can create the possibility for the battery terminals to make reverse contact. This reverse contact can cause a potential for overheating. | 終了 |
| Z-0833-2020 NBW | クラス II | 2019.12.02 | Polymer Technology Systems, Inc. | One brand of batteries have a small dimensional difference in the negative button terminal, which, when the batteries are inserted incorrectly, can create the possibility for the battery terminals to make reverse contact. This reverse contact can cause a potential for overheating. | 終了 |
510(k)(市販前届出)
全 509 件| No. | 番号 | 機器名 | 申請者 | 決定日 | 種別 | 概要 |
|---|---|---|---|---|---|---|
| 1 | K262116 | TRUE METRIX Self Monitoring Blood Glucose System | Trividia Health, Inc. | 2026.07.23 | 特別(Special) | |
| 2 | K250085 | On Call® Sure GK Blood Glucose & Ketone Monitoring System; On Call® Sure Sync GK Blood Glucose & Ketone Monitoring System | ACON Laboratories, Inc. | 2025.10.10 | 通常(Traditional) | - |
| 3 | K243060 | TeleRPM Gen2 Blood Glucose Monitoring System | Guangdong Transtek Medical Electronics Co., Ltd. | 2025.01.30 | 通常(Traditional) | |
| 4 | K240637 | RIGHTEST Blood Glucose Monitoring System Max Tel | Bionime Corporation | 2024.11.04 | 通常(Traditional) | |
| 5 | K240640 | Sejoy Blood Glucose Monitoring System; Sejoy Advance Link Blood Glucose Monitoring System | Sejoy Biomedical Co., Ltd. | 2024.10.08 | 通常(Traditional) | |
| 6 | K241787 | CONTOUR® PLUS BLUE Blood Glucose Monitoring System; CONTOUR® NEXT GEN Blood Glucose Monitoring System | Ascensia Diabetes Care U.S., Inc. | 2024.08.27 | 通常(Traditional) | |
| 7 | K222126 | VivaChek Fad Blood Glucose Monitoring System, VivaChek Fad Smart Blood Glucose Monitoring System, VivaChek Fad Sync Blood Glucose Monitoring System | Vivachek Biotech (Hangzhou) Co., Ltd. | 2024.08.16 | 通常(Traditional) | |
| 8 | K241304 | WaveSense Jazz Blood Glucose Monitoring System | Agamatrix | 2024.06.06 | 特別(Special) | |
| 9 | K231679 | CONTOUR® PLUS BLUE Blood Glucose Monitoring System | Ascensia Diabetes Care | 2024.02.23 | 通常(Traditional) | |
| 10 | K231192 | RIGHTEST Blood Glucose Monitoring System Max Tel | Bionime Corporation | 2024.01.19 | 通常(Traditional) | |
| 11 | K233058 | VivaChek Link Plus Blood Glucose Monitoring System | Vivachek Biotech (Hangzhou) Co., Ltd. | 2023.12.22 | 通常(Traditional) | |
| 12 | K231476 | TRUENESS AIR Blood Glucose Monitoring System; TRUENESS Blood Glucose Monitoring System | Sinocare, Inc. | 2023.12.01 | 通常(Traditional) | |
| 13 | K230625 | ReliOn Premier BLU Blood Glucose Monitoring System | I-Sens, Inc. | 2023.08.10 | 特別(Special) | |
| 14 | K213131 | Accu-Chek Guide Solo diabetes manager blood glucose monitoring system | Roche Diabetes Care GmbH | 2023.08.10 | 通常(Traditional) | |
| 15 | K223722 | MIO Blood Glucose Monitoring System | Mio Labs, Inc. | 2023.06.28 | 通常(Traditional) | |
| 16 | K222234 | GlucoSure ADVANCE Link Blood Glucose Monitoring System | Apex BioTechnology Corp. | 2022.12.21 | 特別(Special) | |
| 17 | K223293 | CONTOUR® NEXT GEN Blood Glucose Monitoring System | Ascensia Diabetes Care U.S., Inc. | 2022.11.18 | 特別(Special) | |
| 18 | K220421 | BGM039 Blood Glucose Monitoring System, BGM039 Link Blood Glucose Monitoring System | Apex BioTechnology Corp. | 2022.11.04 | 特別(Special) | |
| 19 | K213061 | SuperCheck Pro Blood Glucose Monitoring System | Ok Biotech Co., Ltd. | 2022.10.07 | 通常(Traditional) | |
| 20 | K212248 | GlucoLeader Enhance 2 Blood Glucose Monitoring System | Hmd Biomedical, Inc. | 2022.08.29 | 特別(Special) |
出典の openFDA は各 510(k) の主要(primary)product code のみを収録しているため、副次コードを含む FDA 公式データベースの検索結果とは件数が異なる場合があります。 FDA 510(k) データベースで確認
PMA(市販前承認)
この product code の PMA 情報はありません。
不具合報告(MAUDE)トレンド
米国不具合報告検索で詳しく見る出典: openFDA(U.S. FDA) のデータをそのまま掲載しています。内容の正確性・最新性は保証されません。FDA が本サイトの内容を承認・保証するものではありません。
報告の存在は、機器と事象の因果関係を意味しません。報告件数を機器間の不具合発生率の比較に用いることはできません。
各データセット(510(k)・PMA・MAUDE・回収・Warning Letter)の解説は 米国FDA情報の概要 を参照してください。
出典: openFDA(U.S. FDA) のデータをそのまま掲載しています。内容の正確性・最新性は保証されません。FDA が本サイトの内容を承認・保証するものではありません。
取得日: 2026.09.07
各データセット(510(k)・PMA・MAUDE・回収・Warning Letter)の解説は 米国FDA情報の概要 を参照してください。